Key facts
- Vakona’s last known valuation is $47.8M (Oct 2023).
- It has raised $4.8M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Almi Invest, Anders Bergkvist, Execa Allocation, Partnerinvest Norr, Phase2Phase Biopharma — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Vakona
- ·The full record, as it builds
Funding rounds
No funding rounds for Vakona are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vakona
Developer of acne drugs designed to provide novel, efficient and antibiotic-free treatment for acne. The company develops drugs for acne, based on a protein from a skin bacterium that is normally found on our skin and can be used by applying skin cream by acne patients, enabling an effective treatment option for people suffering from acne problems.
- Sector
- Healthcare
- HQ
- Umeaa, Sweden
- Founded
- 2020
- Employees
- 1
- Website
- vakona.se/
- Ownership
- Privately Held (backing)
Vakona doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vakona shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vakona in its N-PORT filings yet. We sweep new filings monthly.